Orchid Pharma: Investec initiates coverage with 'buy', sees 23% upside – 5 key reasons
Despite an over 86 percent gain in the stock in 2023 YTD, domestic brokerage house Investec sees pharma firm Orchid Pharma (ORCD) rising another 23 percent in the next 12 months. The brokerage has initiated coverage on the stock with a ‘buy’ call and a target price of ₹800.
Supriya Aarti Business Expansion Dhanuka Group Contract Development Manufacturing Organization Production Linked Incentive
Source: livemint.com